newsletter masthead
May 31, 2019
MEMBER/CENTER HIGHLIGHTS
50 Days Until "Bike to Cure" Weekend: Team Case CCC Prepares for VeloSano 6
As the weather heats up, training rides are well under way for members of the Case Comprehensive Cancer Center's VeloSano team of employees and friends who have joined the movement to raise money for the cause. 100% of the money the team raises will support lifesaving cancer research in Northeast Ohio's top-tier hospitals and research institutions and researchers and trainees who participate in VeloSano are eligible to apply for special funding opportunities.

To-date, Team Case CCC has 47 members who are committed to cancer research, prevention, treatment and cures and have raised $17,860 and counting!

Getting involved is easy!
  • RIDE with us during Bike to Cure Weekend July 19-21. Jerseys will be provided by the Case CCC. Contact team captains Caroline El Sanadi or Mary Wright for our registration waiver code.
  • DONATE to any rider on our team or to the team as a whole.
  • VOLUNTEER for our cheer station and keep everyone motivated as they ride. Friends, families and children are welcome to join in the fun!
  • PARTY with us at the Tavern of Little Italy for our Fundraiser Bash next Friday, June 7 from 5-8 pm. Tickets are $40 and include 2 drink tickets, 1 raffle ticket, food, live entertainment and valet parking.
American Society of Clinical Oncology Annual Meeting 2019: Highlights from the Case Comprehensive Cancer Center
The 2019 American Society of Clinical Oncology (ASCO) Annual Meeting will take place today through Tuesday, June 4, 2019 in Chicago, IL.

The Case Comprehensive Cancer Center (Case CCC)
has  compiled a list of  presentations, session chairs,
oral abstract sessions,
posters and abstracts from Cleveland-based institutions including Cleveland Clinic, University Hospitals Cleveland Medical Center and Case Western Reserve University. We wish the best of luck to all presenters and attendees and safe travels to Chicago! Read highlights>

The Case CCC is also glad to share your takeaways on social media; simply tag us on Twitter @CaseCCC! Get ready for the weekend with the ASCO Social Media Guide to #ASCO19!
Two-year Master's Level Program Focuses on Regenerative Medicine and Entrepreneurship
The RGME is the first two-year master's level program in Ohio focused on Regenerative Medicine and Entrepreneurship. 

Students enrolled in the RGME program will have access to cutting-edge clinical and research facilities along with small biotechnology companies within the network of the National Center for Regenerative Medicine (NCRM).

This unique, interdisciplinary program will provide a rigorous educational pathway targeting individuals seeking the advanced skills and training required to excel in the unique workforce necessary to support the exponential growth and application of the field of regenerative medicine. The Master's program in RGME will train individuals to work in academic, commercial, and clinical settings to support cellular manufacturing, biotechnology innovation, legal and compliance, financial analyst and venture capital, and business development activities taking advantage of our strengths across the disciplines of regenerative medicine as a whole. Program details>
MARK YOUR CALENDARS
Race for the Place 2019
Sunday, June 2 | Beachwood Place
Celebrating 20 years of serving our community, The Gathering  Place is hosting its annual " Race for the  Place" 5K and 1-mile run/walk at Beachwood  Place on National Cancer Survivors Day, Sunday, June 2. Proceeds from  Race for the  Place help support their free programs and services. The schedule for Sunday's event is as follows:

7:30 am    Race Day Registration
8:00 am    Celebration Village Opens
8:45 am    Survivor Ceremony
9:00 am    5K and 1 Mile Begin
10:30 am  Awards Ceremony

The Gathering  Place is a caring community that supports, educates and empowers individuals and families currently coping with the impact of cancer in their lives through programs and services provided  free of chargeJoin or give to Team Case CCC>
ASCO Review
June 26 | InterContinental Hotel & Conference Center

Don't forget to register for the ASCO Review course by 5:00 PM EST, Monday, June 24. The ASCO Review will be held  Wednesday, June 26, 2019 at the InterContinental Hotel & Bank of America Conference Center. 

The course will provide practicing hematologists, medical oncologists, radiation oncologists and oncology nurses with current data and information that is being presented at the meeting. Free registration includes syllabus, continental breakfast, breaks and lunch.  Register now>
FUNDING OPPORTUNITIES
VeloSano Catalyst Fellowship
Deadline: 5 pm, June 7, 2019

With the generous support from VeloSano Bike to Cure 2018, the Case CCC is providing funding for  Case CCC Trainee Associate Members  to perform their "dream experiment."

The experiment should catalyze highly innovative and impactful projects and help strengthen fellowship and career development grant applications. The intent of the award is to support a single or limited set of innovative experiments, not for general laboratory supplies/projects or maintenance of the trainee's project. Eligibility and application instructions>
Opportunities for Drug Discovery Pilot Projects
Deadline: Open until 5 projects awarded


To improve the discovery and advancement of Case CCC logo innovative cancer therapeutics, the Case Comprehensive Cancer Center is providing seed funding for the development of drug screening assays within the  Small Molecule Drug Development Shared Resource  (SMDD). This RFA is open to all Case CCC Members and applications will be accepted immediately on a rolling basis until all pilot award slots (5) are filled.

Assay development within the SMDD will transpire in two distinct phases:

Phase I: Assay Development
  • Up to 5 projects will be selected for assay development within the SMDD in collaboration with Yuriy Federov, Managing Director of the Shared Resource.
  • Potential drug targets must be justified and functionally validated by the PI.
  • Assay development can transpire over a period of one year.
  • The award will cover up to $10,000 of SMDD facility services for each awardee. Funds will be distributed directly to SMDD. 
Phase II: High-throughput Screening
  • Based on potential screening robustness, up to 2 projects (from the group of Phase I awardees) will be selected for high-throughput library screening within the SMDD.
  • Phase II funds (up to $50,000 per awardee) will be allocated for expenses occurred for high-throughput screening within SMDD, and for laboratory-based validation analyses.
Award Description
  • Up to 5 research projects will be funded for Phase I, with 2 research project moving forward for Phase II. Total funds committed to this RFA are $150,000.
  • Each Phase I research project can request services of up to $10,000 for one year, while selected Phase II research projects can request services of up to $50,000 for one year.
Funding Criteria
  • Open to all Case CCC members
  • Potential drug targets must be justified and supported by compelling validation studies to be deemed responsive for this RFA
  • While investigators can be collaborators on multiple applications, only one application will be accepted per lead PI

Opportunities for Pilot Projects from Cancer Innovation Award
Deadline: June 28, 2019


The Case Comprehensive Cancer Center is providing seed funding for highly innovative and impactful proposals that will generate key data for larger, nationally competitive grants. 
Projects must be transformative in nature and may focus on technology development, innovative biological or therapeutic questions, novel concepts in catchment-based research, or topics that have the potential to overturn dogma. Investigators should submit novel ideas that are high risk and exceptionally innovative.
This RFA is open to all Case CCC Members. Proposals cannot be concurrently funded by other sources or by the Cancer Center.

Award Description
  • Up to 4 research projects will be funded. Total funds committed to this RFA are $300,000.
  • Each research project can request a budget of up to $75,000 for one year.
  • Research projects should be completed within one year.
  • Funds must be expended within the 12 month funding period as cost extensions will not be granted.
Funding Criteria
  • Strong investigative teams of Case Comprehensive Cancer Center members.
  • Projects must be  highly innovative and potentially transformative  to be deemed responsive to this RFA.
  • All materials to complete the project (IRB, bio-samples, reagents, mice imaging data) should be in-hand or readily available. Collection of new patient cohorts as the primary focus of the work is not responsive to this RFA.
  • Projects must have a high likelihood of subsequent national-level funding.
  • While investigators can be collaborators on multiple applications, only one application will be accepted per lead PI. And PIs are allowed one award per year (i.e., no concurrent awards).
  • All funds for shared resources must involve Case CCC facilities unless the use of a shared resource(s) at another NCI-funded institution is sufficiently justified.
Quality of Care & Clinical Care Pathways in Unresectable Stage III/Stage IV NSCLC Research Opportunity
Deadline: July 9, 2019

National Comprehensive Cancer Network® (NCCN®) is NCCN logo pleased to announce that it is collaborating with AstraZeneca Pharmaceuticals (AstraZeneca) to offer a new opportunity to improve patient care and outcomes in advanced non-small cell lung cancer (NSCLC). The Request for Proposals (RFP) outlines the scope and process that will be followed for the submission of Letters of Intent (LOI).

The intent of this RFP is to encourage NCCN Member Institutions to submit LOIs describing concepts for developing, implementing, and evaluating health care provider performance and/or health care quality improvement initiatives to enhance patient care and outcomes in unresectable stage III NSCLC patients and stage IV NSCLC patients receiving first line therapy. Log in to the NCCN Oncology Research Program site to view grant opportunities>

NCCN views this collaboration with AstraZeneca as clear recognition of the advantages offered to NCCN Member Institutions through the NCCN Oncology Research Program. Questions regarding this RFP, may be directed in writing to Nicole Kamienski, Research Study Associate, Oncology Research Program at kamienski@nccn.org.
IN THE NEWS
Healio - May 24, 2019
Director of the Cleveland Clinic's Center for Clinical Artificial Intelligence  Aziz Nazha, MD elaborates on  a computer model at that allows them "to push the envelope of these technologies in health care."
NIH BULLETIN - Notices and Funding Opportunities
Notices
Notice of Correction to RFA-CA-19-033 "Improving Outcomes for Pediatric, Adolescent and Young Adult Cancer Survivors (U01 Clinical Trial Required)"

Notice of Special Interest for Small Business in Genomic Medicine Research

Funding Opportunities
Deadline: July 29, 2019

Renewal Application: Critical Path Public Private Partnerships (U18) Clinical Trials Optional(RFA-FD-19-027)
Deadline: July 29, 2019

LOI Deadline: June 21, 2019
IN THIS ISSUE
EVENTSevents
Fri, May 31
Cancelled due to ASCO: Taussig Cancer Institute Grand Rounds

2019 ASCO Annual Meeting
May 31-June 4
Chicago, IL
Sun, June 2
Race for the Place
7:30a Beachwood Place

National Cancer Survivors Day
Mon, June 3
UH HemOnc Recruitment Seminar
Frank Cackowski, MD, PhD
Rogel Cancer Center
Ann Arbor, MI
9a Lakeside 3 Albert Waldo Conf. Rm
Thurs, June 6
Developmental Therapeutics Journal Club
9a N E 6-218

Molecular Biology and Microbiology Seminar
1p SOM W203
Fri, June 7
Taussig Cancer Institute Grand Rounds
Monica Conces, MD
Alok Khorana, MD
Brian Rini, MD
Manasa Vulchi, MD
Cleveland Clinic
"ASCO Oral Presentations"
8a CA5-120

Team Case CCC VeloSano Fundraiser Bash
5-8p Tavern of Little Italy
Mon, June 10
Shared Resources Directors Meeting
12p WRB 1-422D

Genomic Medicine Institute
Scott Lundy, MD, PhD Eng Lab  
"The Microbiome of Male Infertility"
Nick Sarn
Eng Lab
"Decreased Nuclear Pten Increases Microglia Activation and Synaptic Pruning in a Murine Model with Autism-like phenotype"
12p NE1-205
Thurs, June 13
Developmental Therapeutics Journal Club
9a NE6-218

Molecular Biology and Microbiology Virology Journal Club
1p SOM W203
Fri, June 14
Taussig Cancer Institute Grand Rounds
Jaleh Fallah, MD
Jessica Geiger, MD
Nathaniel Rosko, PharmD
Davendra Sohal, MD
"ASCO Oral Presentations"
8a CA5-120

UH Seidman Cancer Center Grand Rounds
8a Wearn 137
ADDITIONAL UPCOMING SYMPOSIUMS & EVENTS
prev-funding
PREVIOUSLY ANNOUNCED OPPORTUNITIES

Deadline: Open

Deadline: Open

Deadline: Open
Case Comprehensive Cancer Center